Long-acting progestins--promise and prospects.
D000818:Animals; D001634:Bibliographies as Topic; D001943:Breast Neoplasms / Q000139:chemically induced; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004285:Dogs; D005260:Female; D000882:Haplorhini; D006801:Humans; D007273:Injections, Intramuscular; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D009644:Norgestrel / Q000008:administration & dosage / Q000627:therapeutic use; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D051381:Rats; D012098:Reproduction / Q000187:drug effects; D014594:Uterine Neoplasms / Q000139:chemically induced
D003277:Contraceptives, Oral, Combined; D003692:Delayed-Action Preparations; D045167:Progesterone Congeners; D009644:Norgestrel; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; C024319:norethindrone enanthate; D009640:Norethindrone